RhumbLine Advisers
JSPR icon

RhumbLine Advisers’s Jasper Therapeutics JSPR Stock Holding History

RhumbLine Advisers’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,594
Closed -$67K – 4200
2025
Q1 		$67K Buy
15,594
+833
+6% +$5.54K ﹤0.01% 3500
2024
Q4 		$316K Buy
14,761
+1,652
+13% +$34.4K ﹤0.01% 2964
2024
Q3 		$247K Sell
13,109
-122
-0.9% -$2.43K ﹤0.01% 3132
2024
Q2 		$300K Buy
+13,231
New +$317K ﹤0.01% 3006

Other funds holding JSPR

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

RhumbLine Advisers's JSPR Position: Q2 2025 in Review

RhumbLine Advisers sold out of Jasper Therapeutics (JSPR) in Q2 2025, closing a stake of 15,594 shares — an estimated $67K sold.

RhumbLine Advisers first reported a position in JSPR in Q2 2024 and held it in 4 quarters. The position peaked at $316K in Q4 2024. 65 funds tracked by Wall St. Rank hold JSPR as of Q2 2025.

  • RhumbLine Advisers reported no remaining Jasper Therapeutics position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 15,594 Jasper Therapeutics shares in Q2 2025, an estimated $67K.
  • RhumbLine Advisers first reported a position in Jasper Therapeutics in Q2 2024 and held it in 4 quarters.
  • RhumbLine Advisers's Jasper Therapeutics position peaked at $316K in Q4 2024.
  • 65 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.